On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group Oregon Compounding Centers, Inc. dba Creative Compounds 1 27 15 Avoiding FDA Warning Letters: Why High Level Biodecontamination Is Essential in Pharma Manufacturing The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling